FindTrial
Sign In

Clinical Feasibility of Blood Biomarkers for Early and Differential Diagnosis of Alzheimer’s Disease in a Prospective Cohort

Clinical Feasibility of Blood Biomarkers for Early and Differential Diagnosis of Alzheimer’s Disease in a Prospective Cohort

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094088
Enrollment
Unknown
Registered
2024-12-17
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjective cognitive decline

Interventions

Gold Standard:Alzheimers disease was diagnosed based on the 2011/2018 NIA-AA dementia criteria and the International Working Group 2 guidelines.
Index test:GFAP, pTau-217, NfL, Aß1-42 and APOE e4

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Participants ranged from 40 to 90 years, with comprehensive clinical and neuropsychological assessments available in the biobank. 2.Diagnoses were made according to internationally recognized criteria.

Exclusion criteria

Exclusion criteria: 1.Exclusions included CNS infections, head trauma, other major neurological diseases, primary psychiatric disorders, and severe systemic conditions (e.g., malignancies).

Design outcomes

Primary

MeasureTime frame
GFAP, pTau-217, NfL, Aß1-42 and APOE e4 levels;Accuracy;Sensitivity;Specificity;—

Countries

China

Contacts

Public ContactJintai Yu

Huashan Hospital, Fudan University

jintai_yu@fudan.edu.cn+86 186 7899 9982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026